Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.3M | $11.8M | $18.5M | $22.2M | $37.1M | $70.2M | $90.0M | $107.9M |
| Cost of revenue | $11.7M | $11.9M | $10.4M | $11.7M | $17.8M | $26.3M | $34.9M | $43.4M |
| Gross profit | $16.7M | −$144.0K | $8.0M | $10.6M | $19.2M | $43.9M | $55.1M | $64.4M |
| Gross margin | 58.9% | -1.2% | 43.6% | 47.5% | 51.9% | 62.6% | 61.2% | 59.7% |
| R&D | $1.8M | $9.0M | $4.5M | $5.6M | $7.6M | $6.4M | $10.6M | $10.3M |
| Operating income | −$32.1M | −$43.2M | −$27.1M | −$26.8M | −$37.9M | −$27.3M | −$24.7M | −$15.4M |
| EBITDA | −$29.5M | −$39.7M | −$24.0M | −$24.1M | −$36.4M | −$30.5M | −$22.0M | −$14.0M |
| Net income | −$32.5M | −$43.1M | −$28.7M | −$29.0M | −$44.0M | −$43.1M | −$38.1M | −$33.5M |
| Net margin | -114.5% | -365.7% | -155.3% | -130.4% | -118.9% | -61.4% | -42.3% | -31.1% |
| EPS (diluted) | -5.63 | -6.89 | -3.44 | -2.38 | -2.78 | -1.66 | -1.16 | -0.67 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds MXDHF.
No tracked institution reports a position in MXDHF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-11-14 | 1-for-10reverse |
No one on the platform has traded MXDHF yet.
| $4265 |
| — |
| HBCNFHealthBeacon plc | $0.50 | +2269.67% | $8M | — |
| IMUNImmune Therapeutics, Inc. | $0.09 | -7.00% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.